The homegrown rare disease treatment ‘Hunterase’ made record-high performance in its exports. By expanding the number of countries in the global market, the company generated over four times its domestic sales overseas.

According to GC Cross on the 5th, Hunterase recorded sales of ₩22.6 billion in Q1 this year. This is a 72.5%, ₩13.1 billion increase from the same period of the previous year. The company had raised around half of the ₩53.2 billion it had made with Hunterase last year in just one quarter this year.

Hunterase, which was approved in 2012 in Korea, is the world’s second treatment for developed Hunter syndrome, which is also known as ‘Mucopolysaccharidosis